Lv11
20 积分 2024-11-20 加入
Pharmacological tools to target NKCC1 in brain disorders
2小时前
待确认
2-Aminopyridines as Potent and Selective Nav1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model
4天前
已完结
An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder
14天前
已完结
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
1个月前
已完结
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
1个月前
已完结
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
1个月前
已完结
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial
2个月前
已关闭
CNS delivery of targeted protein degraders
2个月前
已完结
Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials
2个月前
已完结
Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers
2个月前
已完结
皖公网安备34019202002308
